Menu Menu


AZN Financials       Clear


AZN        0000901832    
Filing Date Form Type Description Document
2021-10-12 6-K AZD7442 PHIII TRIAL POSITIVE IN COVID OUTPATIENTS View Document
2021-10-04 6-K ENHERTU GRANTED BTD FOR BREAST CANCER View Document
2021-10-01 6-K TOTAL VOTING RIGHTS View Document
2021-09-30 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2021-09-29 6-K ASTRAZENECA TO FULLY ACQUIRE CAELUM BIOSCIENCES View Document
2021-09-28 6-K SAPHNELO APPROVED IN JAPAN FOR SLE View Document
2021-09-24 6-K LYNPARZA PROPEL TRIAL MEETS PRIMARY ENDPOINT View Document
2021-09-23 6-K BOARD COMMITTEE CHANGE View Document
2021-09-23 6-K NEW SUSTAINABILITY COMMITTEE OF THE BOARD View Document
2021-09-21 6-K ASTRAZENECA $360M IRISH MANUFACTURING INVESTMENT View Document
2021-09-20 6-K ENHERTU REDUCED RISK OF DISEASE PROGRESSION BY 72% View Document
2021-09-09 6-K IMFINZI IMPROVES SURVIVAL IN NSCLC IN POSEIDON View Document
2021-09-09 6-K FIXED-DOSE COMBINATION OF ALBUTEROL AND BUDESONIDE (PT027) DEMONSTRATED SIGNIFIC View Document
2021-09-03 6-K ULTOMIRIS APPROVED IN EU FOR CHILDREN WITH PNH View Document
2021-09-01 6-K TOTAL VOTING RIGHTS View Document
2021-08-26 6-K FORXIGA APPROVED IN JAPAN FOR CKD View Document
2021-08-26 6-K ALXN1840 WILSON PHASE III MET PRIMARY ENDPOINT View Document
2021-08-20 6-K UPDATE ON ULTOMIRIS PHASE III ALS TRIAL View Document
2021-08-20 6-K AZD7442 PROPHYLAXIS TRIAL MET PRIMARY ENDPOINT View Document
2021-08-16 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2021-08-11 6-K UPDATE ON US REVIEW OF ROXADUSTAT View Document
2021-08-09 6-K FORXIGA APPROVED IN THE EU FOR CKD View Document
2021-08-09 6-K ENHERTU HEAD-TO-HEAD TRIAL MEETS PRIMARY ENDPOINT View Document
2021-08-02 6-K TOTAL VOTING RIGHTS View Document
2021-08-02 6-K SAPHNELO APPROVED IN THE US FOR SLE View Document
2021-07-30 6-K/A FORM 6-K/A View Document
2021-07-30 6-K FORM 6-K View Document
2021-07-27 SC 13G SC 13G View Document
2021-07-26 6-K ULTOMIRIS RECOMMENDED IN EU FOR CHILDREN WITH PNH View Document
2021-07-22 6-K DIRECTORATE CHANGE View Document
2021-07-21 6-K FORM 6-K View Document
2021-07-21 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2021-07-21 6-K TOTAL VOTING RIGHTS View Document
2021-07-21 6-K ACQUISITION OF ALEXION COMPLETED View Document
2021-07-19 F-6EF REGISTRATION OF AMERICAN DEPOSITAR RECEIPT SHARES View Document
2021-07-19 6-K IMFINZI APPROVED IN CHINA FOR EXTENSIVE-STAGE SCLC View Document
2021-07-16 6-K STATUS ON US FDA ADVISORY COMMITTEE FOR ROXADUSTAT View Document
2021-07-14 425 425 View Document
2021-07-14 425 425 View Document
2021-07-14 6-K ASTRAZENECA-ALEXION TRANSACTION CLEARED IN THE UK View Document
2021-07-08 6-K TEZEPELUMAB GRANTED FDA PRIORITY REVIEW FOR ASTHMA View Document
2021-07-06 425 425 View Document
2021-07-06 425 425 View Document
2021-07-06 6-K ASTRAZENECA-ALEXION TRANSACTION CLEARED IN THE EU View Document
2021-07-01 6-K TOTAL VOTING RIGHTS View Document
2021-06-30 425 425 View Document
2021-06-29 11-K FORM 11-K View Document
2021-06-28 6-K FORXIGA RECOMMENDED IN EU FOR PATIENTS WITH CKD View Document
2021-06-28 6-K NIRSEVIMAB PHII/III TRIAL CONFIRMS SAFETY PROFILE View Document
2021-06-24 6-K LYNPARZA APPROVED IN CHINA FOR PROSTATE CANCER View Document
2021-06-23 6-K ORPATHYS APPROVED IN CHINA FOR LUNG CANCER View Document
2021-06-22 6-K KOSELUGO APPROVED IN THE EU FOR CHILDREN WITH NF1 View Document
2021-06-15 6-K UPDATE ON AZD7442 STORM CHASER TRIAL View Document
2021-06-07 6-K CALQUENCE HEAD-TO-HEAD RESULTS VERSUS IBRUTINIB View Document
2021-06-04 425 425 View Document
2021-06-04 425 425 View Document
2021-06-04 6-K LYNPARZA REDUCED RECURRENCE RISK IN BREAST CANCER View Document
2021-06-04 6-K ASTRAZENECA APPOINTS NEW CHIEF FINANCIAL OFFICER View Document
2021-06-03 CERT View Document
2021-06-02 6-K PUBLICATION OF FINAL TERMS View Document
2021-06-01 8-A12B 8-A12B View Document
2021-06-01 6-K BLOCK LISTING INTERIM REVIEW View Document
2021-06-01 6-K TOTAL VOTING RIGHTS View Document
2021-05-28 6-K FORM 6-K View Document
2021-05-28 6-K TAGRISSOAPPROVED IN THE EU FOR THE ADJUVANT TREATMENT OFPATIENTS WITH EARLY-STAG View Document
2021-05-27 424B2 424B2 View Document
2021-05-27 425 425 View Document
2021-05-27 6-K ASTRAZENECA PRICES A EUR800M BOND OFFERING View Document
2021-05-26 6-K ASTRAZENECA PRICES A $7BN BOND OFFERING View Document
2021-05-26 6-K FORM 6-K View Document
2021-05-26 FWP FWP View Document
2021-05-26 FWP FWP View Document
2021-05-25 6-K EMTN PROGRAMME UPDATE - PUBLICATION OF PROSPECTUS View Document
2021-05-24 425 425 View Document
2021-05-24 424B2 424B2 View Document
2021-05-24 F-3ASR F-3ASR View Document
2021-05-24 6-K FORM 6-K View Document
2021-05-21 6-K ASTRAZENECA COVID-19 VACCINE VAXZEVRIA AUTHORISED FOR EMERGENCY USE IN JAPAN View Document
2021-05-18 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2021-05-11 6-K RESULT OF AGM View Document
2021-05-11 6-K SHAREHOLDERS VOTE IN FAVOUR OF ALEXION ACQUISITION View Document
2021-05-07 425 425 View Document
2021-05-07 6-K IMFINZI + TREMELIMUMAB SHOWED SURVIVAL IN POSEIDON View Document
2021-05-06 425 425 View Document
2021-05-05 425 425 View Document
2021-05-04 6-K TOTAL VOTING RIGHTS View Document
2021-05-04 6-K FARXIGA APPROVED IN THE US FOR CKD View Document
2021-04-30 425 425 View Document
2021-04-30 425 425 View Document
2021-04-30 425 425 View Document
2021-04-30 6-K AZN: FIRST QUARTER 2021 RESULTS View Document
2021-04-29 425 425 View Document
2021-04-26 6-K NIRSEVIMAB PHASE III TRIAL MET PRIMARY ENDPOINT View Document
2021-04-26 6-K TAGRISSO ADJUVANT RECEIVES POSITIVE CHMP OPINION View Document
2021-04-26 6-K SELUMETINIB RECOMMENDED FOR EU APPROVAL IN NF1 View Document
2021-04-16 425 425 View Document
2021-04-16 425 425 View Document
2021-04-16 6-K US CLEARANCE OF PROPOSED ACQUISITION OF ALEXION View Document
2021-04-14 6-K TAGRISSO APPROVED IN CHINA IN EARLY LUNG CANCER View Document
2021-04-13 424B3 424B3 View Document

Find registration statements, periodic reports, and other forms by typing ticker symbol of a company.

Ticker:

(402) 804-8299